Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* You must have been diagnosed with schizophrenia or schizoaffective disorder~* You must be able to visit the doctor's office once every two weeks for three months, then once every four weeks for the next three months with a possible bi-weekly visit during the fifth month~* If you are currently taking a medication for schizophrenia or schizoaffective disorder, you have been taking it for at least 30 days without any changes~* If you are a female, you must have a negative pregnancy test and be using an effective method of contraception~Exclusion Criteria:~* You have a diagnosis of bipolar I disorder, diabetes, very high triglyceride level (fasting triglycerides greater than or equal to 500 mg/dL), recent heart attack, stroke, uncontrolled seizures, serious infection, unstable heart disease (such as ischemic heart disease or congestive heart failure), an uncorrected narrow angle glaucoma or human immunodeficiency virus (HIV)~* You have diseases of the intestinal tract, lungs, liver, kidney, nervous or endocrine systems, or blood~* You have a diagnosis of an eating disorder~* You have a history of Parkinson's Disease or any related disorders~* You are allergic to sulfa drugs or any of the medications involved in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): olanzapine plus behavioral information
- Olanzapine + Amantadine (Type: EXPERIMENTAL): Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
- Olanzapine + Metformin (Type: EXPERIMENTAL): Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information

Based on this trial design, predict the completion outcome and termination type (if applicable).